Artigos

Search for articles

BJO Oncology - Placeholder

Strengths, weaknesses, opportunities and threats with the new system of radiotherapy remuneration in Brazil: a critical appraisal

ABSTRACT Objectives: To evaluate the economic impact of the new form of radiotherapy remuneration published by the Ministry of Health. Methods: We design a simulated group of seventy patients from a database of a public institution. We compare the remuneration from SUS old payment methodology (SOPM), with the new form entitled of...
BJO Oncology - Placeholder

Central nervous system metastases of lung adenocarcinoma harboring EGFR-activating mutations: survival results from a multidisciplinary approach, including EGFR-TKIs

ABSTRACT Objectives: Central nervous system (CNS) metastases are frequent in advanced lung adenocarcinomas harboring EGFR-activating mutations. However, the best treatment approach must be defined. We aimed to evaluate the effectiveness of a multidisciplinary approach for CNS metastases in patients previously untreated with EGFR tyrosine kinase inhibitors (EGFRTKIs). Methods: We performed a retrospective...
BJO Oncology - Placeholder

Efficacy of osimertinib in advanced T790M-positive NSCLC after progression to prior EGFR-TKI: real world data from a Brazilian cohort

ABSTRACT Objectives: Osimertinib is a third-generation EGFR inhibitor with activity against both sensitizing and resistance mutations. Following results of the phase III study, AURA3, which led to the approval of osimertinib worldwide, we have conducted ASTRIS with the aim of confirming the efficacy and safety of osimertinib. Methods: This is a phase...
BJO Oncology - Placeholder

Factors associated with chemotherapy toxicity in outpatients: a cohort study

ABSTRACT Objectives: to identify the occurrence of toxicity associated with chemotherapy and predictors factors of hospitalization, delayed treatment, abandonment, treatment suspension or death. Methods: 126 patients with cancer were in a prospective cohort study, conducted between July/2012 and january/2013, they were interviewed before treatment and after completion of the 1st, 2nd and...
BJO Oncology - Placeholder

How is advanced melanoma treated in the Public Health System in Brazil: a call for change.

ABSTRACT Introduction: Treatment of advanced melanoma has been revolutionized in the last decade. The adoption of new treatments is necessary in order to offer significantly longer survival. Objective: To evaluate how patients are being treated for advanced melanoma at the Public Health System in Brazil. Methods: We evaluated the Authorization of Ambulatory Care...
BJO Oncology - Placeholder

Prognostic Factors Associated with the Efficacy of Hepatic Transarterial Embolization in Patients with Neuroendocrine Tumors

ABSTRACT Introduction: To evaluate the safety and efficacy of hepatic transarterial embolization (TAE) or transarterial chemoembolization (TACE) in patients with irresectable liver metastases from neuroendocrine tumors (NETs) treated at two Brazilian cancer centers. Methods: Retrospective multicenter analysis of patients (pts) with histological diagnosis of neuroendocrine tumor of any origin with unresectable and...
BJO Oncology - Placeholder

Barriers to participation in clinical trials: cross-sectional study on perceptions of oncology patient advocacy group webpage in Brazil

ABSTRACT Introduction: Clinical trials (CT) represent an important alternative treatment for oncologic patients. Also, CTs represent an essential step to development of improved therapeutic strategies. However, little is known on Brazilian perception regarding CT. The aim of this survey was to describe the overall perception of CT in Brazilian participants of...
BJO Oncology - Placeholder

Induction chemotherapy with cisplatin plus weekly paclitaxel followed by chemoradiotherapy for locally advanced squamous cell carcinoma of the head and neck

ABSTRACT The paclitaxel-cisplatin is a non-infusional alternative for induction chemotherapy (IC) for LASCCHN based on phase-II trials. Here, we describe our institutional experience with this combination in Southern Brazil. Methods: Thirty-three consecutive patients with unresectable LASCCHN were selected between April/2012 and June/2014. They received weekly paclitaxel 80mg/m2 on days 1, 8,...
BJO Oncology - Placeholder

Prognostic impact of and mutations in lung cancer survival during pre-tki era: the real scenario at a cancer public center of reference in Brazil EGFR KRAS

ABSTRACT Objective: To evaluate the genetic tests is fundamental for the adequate treatment of non-small cell lung cancer (NSCLC) with tyrosine kinase inhibitors (TKI). Given that access to this evaluation is still limited for those who depend on the Brazilian Public Health System, it seems important to provide regulatory agencies with...
BJO Oncology - Placeholder

Treatment choices in metastatic colorectal cancer according to sidedness and RAS/BRAF status: a national survey by the Brazilian Gastrointestinal Tumors Group (GTG)

ABSTRACT Objectives: Tumor sidedness and RAS/BRAF status have changed the treatment landscape of metastatic colorectal cancer (mCRC). This study was performed to understand the first line choices of Brazilian oncologists for patients with mCRC, especially in the emergent context of tumor sidedness and RAS/BRAFV600E status. Methods: This was a cross-sectional electronic survey...